Immune system

Agenus to Host “The Road Taken” R&D Event on November 12, 2022

Retrieved on: 
Wednesday, October 5, 2022
U.S. Securities and Exchange Commission, Therapy, Webcast, MedStar Georgetown University Hospital, Investor, VP, List of lifetime achievement awards, Infection, GMP, The Road Taken, Annual report, NASDAQ, Prudential Tower, Research, Twitter, Division, Security (finance), Risk, Cancer, Immune system, Company, MD, Mink, Immunotherapy, Safety, GLOBE, Principal, Pharmaceutical industry, Agenus

The Road Taken will feature both key opinion leaders at the forefront of immunotherapy development for cancer and Agenus expanding leadership team.

Key Points: 
  • The Road Taken will feature both key opinion leaders at the forefront of immunotherapy development for cancer and Agenus expanding leadership team.
  • The event will be webcast live and institutional investors and research analysts are invited to attend in person.
  • Individuals interested in attending the event in person should contact Agenus Investor Relations at [email protected] .
  • Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release.

Evaxion welcomes Per Norlén as new CEO.

Retrieved on: 
Wednesday, October 5, 2022
U.S. Securities and Exchange Commission, Omicron, SEC, Government, Prevalence, Growth, NASDAQ, Drug development, Patient, Coronavirus, Cancer, Technology, Immune system, Company, Delta, CEO, Melanoma, GLOBE, Forward-looking statement, COVID-19, Pharmaceutical industry, Pharma

Evaxion has emerged from being an under-the-radar start-up to becoming a clinical stage biotech company leading the development of tailored cancer immunotherapies, individually designed for each patient.

Key Points: 
  • Evaxion has emerged from being an under-the-radar start-up to becoming a clinical stage biotech company leading the development of tailored cancer immunotherapies, individually designed for each patient.
  • I am convinced that Evaxion is on to something extremely important that holds the potential to become a game-changer for patients with metastatic cancer.
  • This is clearly within reach with a newly initiated phase 2b trial in melanoma that will hopefully confirm the very promising phase 1 efficacy signals, says Per Norln, CEO at Evaxion.
  • Per Norln is joining the company as an experienced leader bringing the necessary expertise and competences to bring Evaxion from an innovative early stage to the next level.

Palleon Co-Founder Dr. Carolyn Bertozzi Awarded Nobel Prize in Chemistry for Pioneering Methods of Studying Glycobiology

Retrieved on: 
Wednesday, October 5, 2022
Research, Genetics, Fitness & Nutrition, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Method, Medicine, IND, Immunity, University of Copenhagen, Nobel Prize, Neoplasm, Patient, Drug development, Biology, Biotechnology, Research, Partnership, Cancer, University, Nobel Prize in Chemistry, Scripps Research, Immune system, Drug discovery, Pharmacokinetics, Safety, Medication, Glycosylation, Copenhagen, Inflammation, Click chemistry, NCT, Secondary research, Pharmaceutical industry, Palleon, Chemistry

Palleon Pharmaceuticals , a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that the companys scientific co-founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry.

Key Points: 
  • Palleon Pharmaceuticals , a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that the companys scientific co-founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry.
  • Dr. Bertozzi invented the field of bioorthogonal chemistry, which allows researchers to chemically modify molecules in living systems without interfering with normal cell functions.
  • Dr. Sharpless is an American scientist who previously won the Nobel Prize for Chemistry in 2001.
  • Palleon Pharmaceuticals is a biotechnology company pioneering glyco-immunology drug development to transform the treatment of cancer and inflammatory diseases.

Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, TCR, U.S. Securities and Exchange Commission, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Renal cell carcinoma, Therapy, Investor, Therapeutic index, CD3, Cytokine, Degenerative disease, MCRPC, NASDAQ, Antibody, Patient, Security (finance), Annual report, Immunotherapy, Technology, Private Securities Litigation Reform Act, RCC, Form 10-K, Trial of the century, Company, Immune system, IL18, Society, PD-1, Kidney cancer, Prostate cancer, Forward-looking statement, ENPP3, Poster, Vaccine, Medical imaging, Cancer

In the poster hall, odd numbered posters will be displayed on Thursday, November 10, and even numbered posters will be displayed on Friday, November 11.

Key Points: 
  • In the poster hall, odd numbered posters will be displayed on Thursday, November 10, and even numbered posters will be displayed on Friday, November 11.
  • Posters will be archived under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com .
  • Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases.
  • More than 20 candidates engineered with Xencor's XmAb technology are in clinical development, and three XmAb medicines are marketed by partners.

Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
U.S. Securities and Exchange Commission, Scientific programming language, Therapy, SITC, Infection, GMP, Annual report, NASDAQ, Neoplasm, Twitter, Security (finance), Annual general meeting, Immunotherapy, Risk, Society for Immunotherapy of Cancer, Cancer, University, Publication, Company, Immune system, Doctor of Philosophy, Education, Mink, Society, FC, Drug discovery, 2021 Essex County Council election, Toxic epidermal necrolysis, GLOBE, Clinical research, Pancreatic cancer, Leadership, Vaccine, Pharmaceutical industry, MD, Agenus

To register for the webinar, please visit the Educational and Scientific Programs section of the SITC website .

Key Points: 
  • To register for the webinar, please visit the Educational and Scientific Programs section of the SITC website .
  • Updated data presented at the conference will be available to view in the Publications section of the Agenus website (https://agenusbio.com/publications) following the SITC Annual Meeting.
  • Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections.
  • Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release.

OncoSec Announces Pipeline Prioritization and Workforce Reduction

Retrieved on: 
Tuesday, October 4, 2022
SAN, Doctor of Philosophy, SEC, Annual report, NASDAQ, RECIST, Electroporation, Technology, Private Securities Litigation Reform Act, Form 10-K, Tumor microenvironment, Immune system, Company, U.S. Securities and Exchange Commission, CEO, Form, Securities & Exchange Commission of Pakistan, ORR, Endpoint security, Melanoma, Forward-looking statement, Risk, Vaccine, Pharmaceutical industry

Oncosec is reducing its staff by approximately 45% and prioritizing clinical pipeline activities to reduce operating expenses.

Key Points: 
  • Oncosec is reducing its staff by approximately 45% and prioritizing clinical pipeline activities to reduce operating expenses.
  • Updated guidance on the pivotal Phase 2b KEYNOTE-695 trial in metastatic melanoma, is as follows.
  • "Since joining as CEO my focus has been on reviewing all aspects of our technology and pipeline.
  • OncoSec Medical Incorporated (the "Company," "OncoSec," "we" or "our") is a biotechnology company focused on developing intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer.

NASA's SpaceX Crew-4 Astronauts to Discuss Mission, Splashdown

Retrieved on: 
Tuesday, October 4, 2022
International Space Station, Television, News, Astronaut, Moon, Orbit, Technology, European Space Agency, ESA, Research, Exploration, SpaceX, Multimedia, NASA TV, Ageing, Immune system, Commercial Crew Program, Rotation, NASA, Emulsion, International Space Station programme, SpaceX Crew-4, Johnson Space Center, Hearing, Artemis, Social media, EDT, Noise, Communications satellite, Samantha Cristoforetti, Mars

WASHINGTON, Oct. 4, 2022 /PRNewswire/ -- NASA's SpaceX Crew-4 astronauts will answer media questions at 11:55 a.m. EDT Tuesday, Oct. 11, about their time aboard the International Space Station.

Key Points: 
  • WASHINGTON, Oct. 4, 2022 /PRNewswire/ -- NASA's SpaceX Crew-4 astronauts will answer media questions at 11:55 a.m. EDT Tuesday, Oct. 11, about their time aboard the International Space Station.
  • NASA astronauts Kjell Lindgren , Bob Hines , and Jessica Watkins , as well as ESA (European Space Agency) astronaut Samantha Cristoforetti will participate in the news conference from orbit.
  • The SpaceX Dragon Freedom spacecraft will undock from the space station later this month, splashing down off the coast of Florida to conclude their mission.
  • Crew-4 is the fourth crew rotation mission with SpaceX for the agency's Commercial Crew Program .

Practice Changing Study Highlights Value of Starting Immunotherapy Before Targeted Therapies in Patients with BRAF-Mutated Melanoma

Retrieved on: 
Tuesday, October 4, 2022
DREAM, Nation, Cancer, MEK, Hospital, American Journal of Clinical Oncology, Melanoma, American Cancer Society, Mortality, NCI, Neoplasm, Physician, Ipilimumab, Immunotherapy, Survival, Research, Disease, New Jersey-New York 7 Conference, NCI-designated Cancer Center, Clinical trial, Hackensack Meridian Health, New, Multimedia, Protein, Nursing, BRAF, Patient, Progression-free survival, September 27, View, Annual report, Mutation, Immune system, MedStar Health, CI, Georgetown Lombardi Comprehensive Cancer Center, Hackensack Meridian School of Medicine, Strathcona County, Georgetown, Journal, Oncology, Nivolumab, Education, Aftercare, Diagnosis, MedSTAR, Dabrafenib, III, Pharmaceutical industry, Vaccine

Targeted medications and immunotherapy have become standard care for people with advanced melanoma.

Key Points: 
  • Targeted medications and immunotherapy have become standard care for people with advanced melanoma.
  • Starting in 2015, 265 patients with metastatic melanoma were randomly assigned to one of two groups.
  • One group started treatment with combination ipilimumab and nivolumab immunotherapy, and the second group began with the targeted therapies dabrafenib and trametinib.
  • Two-year overall survival was 72% among patients who received combination immunotherapy first versus 52% for those who took the two targeted therapies as initial treatment.

The Society for Immunotherapy of Cancer (SITC) Publishes a Checklist to Maximize the Benefit to Patients for Clinical Trials in Immuno-oncology

Retrieved on: 
Tuesday, October 4, 2022
Solution, YouTube, Manuscript, Society, Biology, Immunity, LinkedIn, Immunotherapy, Disease, Clinical trial, MD, Twitter, Neoplasm, Immune system, Probability, Society for Immunotherapy of Cancer, Science, Journal, SITC, Patient, Checklist, III, Pharmaceutical industry, Cancer

MILWAUKEE, Oct. 4, 2022 /PRNewswire-PRWeb/ -- No uniform method has been established to predict the probability of success for individual clinical trials. To help identify clinical trials with a high likelihood of offering benefit to patients, the Society for Immunotherapy of Cancer (SITC) brought together a team of experts in immuno-oncology to create a conceptual framework for potential value in phase III studies evaluating immunotherapy combinations. The framework, put forth as a checklist for the oncology community, is published in a new manuscript, "Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)," now available in the Journal for ImmunoTherapy of Cancer, the society's open-access, peer-reviewed online journal.

Key Points: 
  • MILWAUKEE, Oct. 4, 2022 /PRNewswire-PRWeb/ -- No uniform method has been established to predict the probability of success for individual clinical trials.
  • "Immuno-oncology clinical trials are of the utmost importance to provide new effective drugs for cancer patients," said SITC President Patrick Hwu, MD.
  • "This checklist provides investigators, and other key stakeholders, a roadmap to identify and prioritize phase III clinical trials that are likely to offer the greatest benefit to patients."
  • Phase III trials are how new treatments for cancer demonstrate benefit and establish their place in the treatment paradigm to offer improved outcomes for patients.

Global Vaccine Delivery Devices Market Report 2022: Technological Advancements in the Systematic Delivery of Vaccines to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 4, 2022
Pharmaceutical, Health, Medical Devices, Vaccine, Non-governmental organization, Toxicity, Anthrax Vaccine Immunization Program, Vaccine-preventable diseases, Disability, Coronavirus, Disease, Research, Prevalence, CAGR, Antibody, COVID-19, Infection, Immune system, Dendrimer, Microparticle, Electroporation, Death, USERN Prize, Investment, Liposome, Antigen, Nanoparticle, Pharmaceutical industry, Growth

The "Vaccine Delivery Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vaccine Delivery Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global vaccine delivery devices market reached a value of US$ 6.44 Billion in 2021.
  • Vaccine Delivery Devices Market Trends:
    Technological advancements in the systematic delivery of vaccines, such as micro-needles and electroporation, represent one of the key factors driving the market.
  • This, along with the rising research in the field of vaccines and the development of new vaccine delivery devices around the world, is propelling the growth of the market.